AR104461A1 - Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas - Google Patents
Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estasInfo
- Publication number
- AR104461A1 AR104461A1 ARP160101237A ARP160101237A AR104461A1 AR 104461 A1 AR104461 A1 AR 104461A1 AR P160101237 A ARP160101237 A AR P160101237A AR P160101237 A ARP160101237 A AR P160101237A AR 104461 A1 AR104461 A1 AR 104461A1
- Authority
- AR
- Argentina
- Prior art keywords
- straight
- branched chain
- chain alkyl
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la estructura fórmula (1) o una sal o un solvato de aquel aceptables desde el punto de vista farmacéutico, o un enantiómero o un diastereómero de aquel, y en donde R² se selecciona del grupo que consiste en hidrógeno, deuterio, C₁₋₆ alquilo de cadena lineal o ramificada, C₃₋₆ cicloalquilo, C₆₋₁₀ arilo, heteroarilo monocíclico o bicíclico, que comprende anillos de 5 y/o 6 miembros, (aril)C₁₋₆ alquilo de cadena lineal o ramificada, (heteroaril)C₁₋₆ alquilo de cadena lineal o ramificada, (heterociclil)C₁₋₆ alquilo de cadena lineal o ramificada, (C₁₋₆ alquil de cadena lineal o ramificada)arilo, (C₁₋₆ alquil de cadena lineal o ramificada)heteroarilo, (C₁₋₆ alquil de cadena lineal o ramificada)heterociclilo, C₁₋₆ perfluoroalquilo de cadena lineal o ramificada, C₁₋₆ alcoxi de cadena lineal o ramificada, C₁₋₆ perfluoroalcoxi de cadena lineal o ramificada, halógeno, ciano, hidroxilo, amino, carboxi, aminocarbonilo, (C₁₋₆ alquil de cadena lineal o ramificada)aminocarbonilamino, (C₁₋₆ alquil de cadena lineal o ramificada)aminocarbonilo, -SOR¹², -SO₂R¹², -NR¹³SO₂R¹², -SO₂NR¹³R¹⁴ y -NR¹³SO₂NR¹⁴R¹⁵; en donde tal alquilo, arilo y heteroarilo se sustituyen, independientemente y de manera opcional, con uno o más sustituyentes seleccionados del grupo que consiste en halo, hidroxi, metoxi, amino, ciano, alquilamino, dialquilamino, CF₃, aminocarbonilo, (C₁₋₆ alquil de cadena lineal o ramificada)aminocarbonilo y C₃₋₆ cicloalquilo; las líneas punteadas al átomo O pueden estar presentes o ausentes, y si están presentes, el anillo resultante forma un epóxido, o si están ausentes, se obtiene un etileno; R³ se selecciona del grupo que consiste en hidrógeno, deuterio, C₁₋₆ alquilo de cadena lineal o ramificada, C₁₋₆ perfluoroalquilo de cadena lineal o ramificada, halógeno y ciano; R⁰ se selecciona de hidrógeno, C₁₋₆ alquilo de cadena lineal o ramificada y C₁₋₆ perfluoroalquilo de cadena lineal o ramificada; R¹, R⁴, R⁵, R⁴, R⁶, R⁷, R⁸, R⁹ y R¹⁰ se seleccionan independientemente de hidrógeno, C₁₋₆ alquilo de cadena lineal o ramificada, C₁₋₆ perfluoroalquilo de cadena lineal o ramificada, C₆₋₁₀ arilo, heteroarilo monocíclico o bicíclico, que comprende anillos de 5 y/o 6 miembros, (aril)C₁₋₆ alquilo de cadena lineal o ramificada, (heteroaril)C₁₋₆ alquilo de cadena lineal o ramificada, heteroarilo, halógeno, ciano, hidroxilo, C₁₋₆ alcoxi de cadena lineal o ramificada, amino, carboxi, aminocarbonilo, (heterociclil)C₁₋₆ alquilo de cadena lineal o ramificada, (C₁₋₆ alquil de cadena lineal o ramificada)arilo, (C₁₋₆ alquil de cadena lineal o ramificada)heteroarilo y (C₁₋₆ alquil de cadena lineal o ramificada)heterociclilo, en donde tal alquilo también se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste en halo, hidroxi, metoxi, amino, alquilamino, dialquilamino, CF₃ y C₃₋₆ cicloalquilo; en donde R⁸ y R⁹ juntos pueden formar un anillo de 3 - 6 miembros que contiene opcionalmente uno o dos átomos de O ó N; R¹¹ es hidrógeno o deuterio; R¹², R¹³, R¹⁴ y R¹⁵ se seleccionan independientemente de hidrógeno, C₁₋₆ alquilo de cadena lineal o ramificada, C₁₋₆ perfluoroalquilo de cadena lineal o ramificada, C₆₋₁₀ arilo, alquilarilo y (aril)C₁₋₆ alquilo de cadena lineal o ramificada; Y es O ó N, en donde cuando Y es N, el enlace punteado es un enlace simple, o N se sustituye con H o alquilo, y el enlace punteado a este está ausente, y cuando Y es O, el enlace punteado a este está ausente; y n y p son independientemente 0, 1 ó 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562155824P | 2015-05-01 | 2015-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104461A1 true AR104461A1 (es) | 2017-07-19 |
Family
ID=55863136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101237A AR104461A1 (es) | 2015-05-01 | 2016-04-29 | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas |
Country Status (8)
Country | Link |
---|---|
US (1) | US10703756B2 (es) |
EP (1) | EP3288943B1 (es) |
JP (1) | JP6761815B2 (es) |
AR (1) | AR104461A1 (es) |
CA (1) | CA2984183C (es) |
ES (1) | ES2928757T3 (es) |
TW (1) | TW201706274A (es) |
WO (1) | WO2016178110A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573967A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
US11957931B2 (en) * | 2017-04-26 | 2024-04-16 | Yale University | Compositions and methods for treating vitiligo |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
TW201920150A (zh) | 2017-08-01 | 2019-06-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak激酶抑制劑之吡唑并及三唑并雙環化合物 |
PL3762368T3 (pl) | 2018-03-08 | 2022-06-06 | Incyte Corporation | ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
CN112823005A (zh) | 2018-08-10 | 2021-05-18 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
CA3125039A1 (en) * | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
CN112430235B (zh) * | 2019-08-26 | 2024-04-05 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
KR102228668B1 (ko) * | 2019-10-08 | 2021-03-17 | (주)부흥산업사 | 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법 |
CN111407767B (zh) * | 2020-03-28 | 2021-05-25 | 中山大学 | 一种磺胺间甲氧嘧啶衍生物在制备抗肿瘤药物中的应用 |
WO2023151069A1 (zh) * | 2022-02-14 | 2023-08-17 | 湖南南新制药股份有限公司 | 吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20004727A3 (cs) | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
MXPA02005675A (es) | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | Compuestos de pirrolo(2,3-d)pirimidina. |
DK1294724T3 (da) | 2000-06-26 | 2006-07-17 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidinforbindelser som immunosuppresive midler |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
AU2003278529A1 (en) | 2002-11-21 | 2004-06-15 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
US7491827B2 (en) | 2002-12-23 | 2009-02-17 | Millennium Pharmaceuticals, Inc. | Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
RU2006109491A (ru) | 2003-08-27 | 2006-08-10 | Байота, Инк. (Au) | Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств |
EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
JP5098843B2 (ja) | 2007-06-29 | 2012-12-12 | Jfeスチール株式会社 | 金属試料中の着目元素の固溶含有率を求める方法 |
DK2247592T3 (da) | 2008-02-25 | 2011-09-26 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitors |
ES2378513T3 (es) | 2008-08-06 | 2012-04-13 | Pfizer Inc. | Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1 |
CN107011330B (zh) | 2009-09-04 | 2020-07-03 | 比奥根Ma公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN103003281A (zh) | 2010-05-20 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为JAK和SYK抑制剂的吡咯并[2,3-b]吡嗪-7-甲酰胺衍生物和它们的用途 |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
MY187446A (en) | 2013-12-05 | 2021-09-22 | Pfizer | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
-
2016
- 2016-04-19 JP JP2017556831A patent/JP6761815B2/ja active Active
- 2016-04-19 CA CA2984183A patent/CA2984183C/en active Active
- 2016-04-19 ES ES16719917T patent/ES2928757T3/es active Active
- 2016-04-19 EP EP16719917.3A patent/EP3288943B1/en active Active
- 2016-04-19 US US15/569,874 patent/US10703756B2/en active Active
- 2016-04-19 WO PCT/IB2016/052220 patent/WO2016178110A1/en active Application Filing
- 2016-04-27 TW TW105113139A patent/TW201706274A/zh unknown
- 2016-04-29 AR ARP160101237A patent/AR104461A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3288943B1 (en) | 2022-09-28 |
TW201706274A (zh) | 2017-02-16 |
CA2984183C (en) | 2021-11-09 |
US10703756B2 (en) | 2020-07-07 |
ES2928757T3 (es) | 2022-11-22 |
JP2018514560A (ja) | 2018-06-07 |
JP6761815B2 (ja) | 2020-09-30 |
CA2984183A1 (en) | 2016-11-10 |
WO2016178110A1 (en) | 2016-11-10 |
EP3288943A1 (en) | 2018-03-07 |
US20190002466A1 (en) | 2019-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104461A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas | |
AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
CR20210083A (es) | Compuestos de anillo fusionado | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
AR123089A2 (es) | Compuesto de piridinona | |
AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
AR092742A1 (es) | Piridinonas antifibroticas | |
PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
AR089285A1 (es) | Derivados de betulina | |
AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
AR099874A1 (es) | CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA | |
AR094550A1 (es) | Inhibidores de btk | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
AR101077A1 (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
AR097435A1 (es) | 6-alquinilpiridinas | |
MX2016012451A (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina. | |
TW201613603A (en) | Pharmaceutical preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |